Literature DB >> 9664773

A symptom checklist to screen for somatoform disorders in primary care.

K Kroenke1, R L Spitzer, F V deGruy, R Swindle.   

Abstract

Current DSM-IV somatoform diagnoses may inadequately capture many somatizing patients in primary care. By using data from two studies (1,000 and 258 patients, respectively), the authors determined 1) the optimal threshold on a checklist of 15 physical symptoms to screen for a recently proposed somatoform diagnosis, multisomatoform disorder (MSD), and 2) the concordance between MSD and somatization disorder. The optimal threshold for pursuing a diagnosis of MSD was seven or more physical symptoms. The majority (88%) of the patients who met criteria for MSD had either full or abridged somatization disorder. MSD was intermediate between abridged and full somatization disorder in terms of its association with functional impairment, psychiatric comorbidity, family dysfunction, and health care utilization and charges.

Entities:  

Mesh:

Year:  1998        PMID: 9664773     DOI: 10.1016/S0033-3182(98)71343-X

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  39 in total

1.  A method for rating charts to identify and classify patients with medically unexplained symptoms.

Authors:  Robert C Smith; Elie Korban; Mohammed Kanj; Robert Haddad; Judith S Lyles; Catherine Lein; Joseph C Gardiner; Annemarie Hodges; Francesca C Dwamena; John Coffey; Clare Collins
Journal:  Psychother Psychosom       Date:  2004 Jan-Feb       Impact factor: 17.659

2.  The cost of somatisation among the working-age population in England for the year 2008-2009.

Authors:  Sarah L Bermingham; Alan Cohen; John Hague; Michael Parsonage
Journal:  Ment Health Fam Med       Date:  2010-06

3.  The Unhappy Triad: Pain, Sleep Complaints, and Internalizing Symptoms.

Authors:  Erin Koffel; Erin E Krebs; Paul A Arbisi; Christopher R Erbes; Melissa A Polusny
Journal:  Clin Psychol Sci       Date:  2016-01-16

4.  Motivation for Psychotherapy and Illness Beliefs in Turkish Immigrant Inpatients in Germany: Results of a Cultural Comparison Study.

Authors:  Hanna Reich; Luisa Bockel; Ricarda Mewes
Journal:  J Racial Ethn Health Disparities       Date:  2014-10-01

Review 5.  Use of psychopharmacological agents for functional gastrointestinal disorders.

Authors:  R E Clouse; P J Lustman
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

Review 6.  Fibromyalgia: a rheumatologic diagnosis?

Authors:  Gerhard K M Endresen
Journal:  Rheumatol Int       Date:  2007-07-20       Impact factor: 2.631

7.  Prevalence and correlates of somatoform disorders in the elderly: Results of a European study.

Authors:  Maria Christina Dehoust; Holger Schulz; Martin Härter; Jana Volkert; Susanne Sehner; Anna Drabik; Karl Wegscheider; Alessandra Canuto; Kerstin Weber; Mike Crawford; Alan Quirk; Luigi Grassi; Chiara DaRonch; Manuel Munoz; Berta Ausin; Anna Santos-Olmo; Arieh Shalev; Ora Rotenstein; Yael Hershkowitz; Jens Strehle; Hans-Ulrich Wittchen; Sylke Andreas
Journal:  Int J Methods Psychiatr Res       Date:  2017-02-01       Impact factor: 4.035

8.  Somatisation and alexithymia in patients with high use of medical care and medically unexplained symptoms.

Authors:  Norman H Rasmussen; David C Agerter; Robert C Colligan; Macaran A Baird; Charles E Yunghans; Stephen S Cha
Journal:  Ment Health Fam Med       Date:  2008-09

9.  Patients presenting with somatic complaints in general practice: depression, anxiety and somatoform disorders are frequent and associated with psychosocial stressors.

Authors:  Nader Haftgoli; Bernard Favrat; François Verdon; Paul Vaucher; Thomas Bischoff; Bernard Burnand; Lilli Herzig
Journal:  BMC Fam Pract       Date:  2010-09-15       Impact factor: 2.497

10.  Severe MUPS in a sick-listed population: a cross-sectional study on prevalence, recognition, psychiatric co-morbidity and impairment.

Authors:  Rob Hoedeman; Boudien Krol; Nettie Blankenstein; Petra C Koopmans; Johan W Groothoff
Journal:  BMC Public Health       Date:  2009-12-01       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.